Ono pays $80M for local rights to trio of Biohaven IgG degraders

Ono Pharmaceutical has acquired regional rights for Japan, South Korea, Taiwan, and ASEAN countries to three Biohaven IgG degrader drug candidates, including a phase 3 asset for Graves' disease, for $80 million upfront plus milestone and profit-sharing payments.

This Wire brief sits within Fusion42's coverage of Biotech.